<DOC>
	<DOC>NCT00409838</DOC>
	<brief_summary>The purpose of the study is to demonstrate the clinical efficacy of abatacept (body-weight tiered dose approximating 10 mg/kg) compared with placebo on a background of methotrexate after 6 months (Day 169) of treatment in Korean patients with active rheumatoid arthritis and an inadequate clinical response to methotrexate</brief_summary>
	<brief_title>A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key Rheumatoid arthritis (RA) for longer than 1 year from the time of the initial diagnosis of RA Patients must have been taking methotrexate for at least 3 months with at least a weekly dose of 15 mg, and a stable dose for 28 days prior to treatment (Day 1) Methotrexate weekly dose as low as 10 mg is permitted for patients who cannot tolerate higher doses Key Evidence (as assessed by the Investigator) of active or latent bacterial or viral infections at the time of potential enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatoid Arthritis, with inadequate response to methotrexate</keyword>
</DOC>